Roles of apolipoproteins B and E in the cellular binding of very low density lipoproteins.
Open accessThe DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
Apoproteins B and E both interact with cellular low density lipoprotein (LDL) apolipoprotein B and E (apo B,E)-receptors, and very low density lipoproteins (VLDL) contain both apo B and apo E. Our aim was to study the relative importance of apo B and apo E in the binding of VLDL subfractions to cells. Two monoclonal anti-LDL-apo B antibodies (464B1B3 and 464B1B6, 2a and 2b, respectively) and two anti-apo E antibodies (1506 A1.4 and 1907 F6.4) were used to inhibit lipoprotein-cell interactions. In confirmation of previous findings, the binding and degradation of 125I-LDL by human fibroblasts were inhibited approximately 90% by antibodies 2a or 2b or the antigen-binding fragments of 2a, whereas the cellular processing of 125I-VLDL3 (Sf20-60), 125I-VLDL2 (Sf60-120), and 125I-VLDL1 (Sf greater than 120) were inhibited by only approximately 50%, approximately 25%, and less than 10%, respectively. The VLDL1-3 and LDL-dependent intracellular esterification of cholesterol with [3H]oleate were inhibited to a similar extent. Other monoclonal anti-human apo B antibodies inhibited lipoprotein-cell interactions much less effectively and nonimmune IgG isolated from mouse serum did not inhibit at all. 20-fold excesses of LDL produced about the same patterns of inhibition of degradation of 125I-VLDL1-3 and LDL by cells as did antibodies 2a and 2b, whereas homologous unlabeled VLDL1-3 in like amounts inhibited the matched 125I-VLDL subfraction more effectively. Two anti-apo E monoclonal antibodies and a polyclonal anti-apo E antibody inhibited cell-mediated degradation of and lipoprotein-dependent cholesterol esterification by VLDL1 but not VLDL3 or LDL. The results suggest that receptor recognition sites on apo E in preference to sites on apo B mediate the cellular binding of hypertriglyceridemic VLDL1. However, the proportion of particles bound via apo B seems to increase as VLDL decreases in size toward LDL, and virtually all of LDL binding is mediated by apo B.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Innerarity, T. L., & Mahley, R. W. (1978) · Biochemistry · doi:10.1021/bi00601a013 · Cited by 433
Havel, R. J., & Kane, J. P. (1973) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.70.7.2015 · Cited by 231
Cited by
Apolipoprotein E polymorphism and atherosclerosis.
Davignon, J., Gregg, R. E., & Sing, C. F. (1988) · Arteriosclerosis: An Official Journal of the American Heart Association, Inc. · doi:10.1161/01.atv.8.1.1 · Cited by 1,981
Chang, K.-S., Jiang, J., Cai, Z., & Luo, G. (2007) · Journal of Virology · doi:10.1128/jvi.01091-07 · Cited by 424
Nakajima, K., Saito, T., Tamura, A., Suzuki, M., Nakano, T., Adachi, M., Tanaka, A., Tada, N., Nakamura, H., Campos, E., et al. (1993) · Clinica Chimica Acta · doi:10.1016/0009-8981(93)90062-9 · Cited by 416
Apolipoprotein-mediated pathways of lipid antigen presentation
Elzen, P. V. D., Garg, S., León, L., Brigl, M., Leadbetter, E. A., Gumperz, J. E., Dascher, C. C., Cheng, T.-Y., Sacks, F. M., Illarionov, P. A., et al. (2005) · Nature · doi:10.1038/nature04001 · Cited by 380
Apolipoprotein E but Not B Is Required for the Formation of Infectious Hepatitis C Virus Particles
Jiang, J., & Luo, G. (2009) · Journal of Virology · doi:10.1128/jvi.01476-09 · Cited by 255
Sehayek, E., & Eisenberg, S. (1991) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)55263-7 · Cited by 249
Effects of PCSK9 inhibition with alirocumab on lipoprotein metabolism in healthy humans
Reyes-Soffer, G., Pavlyha, M., Ngai, C., Thomas, T., Holleran, S., Ramakrishnan, R., Karmally, W., Nandakumar, R., Fontanez, N., Obunike, J., et al. (2017) · Circulation · doi:10.1161/circulationaha.116.025253 · Cited by 240
Demant, T., Bedford, D., Packard, C. J., & Shepherd, J. (1991) · Journal of Clinical Investigation · doi:10.1172/jci115459 · Cited by 145
Buckley, R., Shewring, B., Turner, R., Yaqoob, P., & Minihane, A. M. (2004) · British Journal of Nutrition · doi:10.1079/bjn20041235 · Cited by 118
“However, apoE is also an essential modulator of 30– 50 % of TG-rich lipoprotein clearance by the liver as it acts as a ligand for the hepatic LDL-receptor and the LDL-receptor-related protein (Krul et al. 1985; Tomiyasu et al. 2001).”
BackgroundVéniant, M. M., Pierotti, V, Newland, D., Cham, C. M., Sanan, D. A., Walzem, R. L., & Young, S. G. (1997) · Journal of Clinical Investigation · doi:10.1172/jci119511 · Cited by 100
Krul, E. S., Tikkanen, M. J., & Schonfeld, G. (1988) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)38434-0 · Cited by 50
Self-citation
Metadata
- Authors
- Krul, E. S., Tikkanen, M. J., Cole, T. G., Davie, J. M., & Schonfeld, G.
- Venue
- Journal of Clinical Investigation
- Published
- 1985-02-01
- Volume
- 75
- Issue
- 2
- Pages
- 361-369
- ISSN
- 0021-9738 (ISSN-L)
- OpenAlex
- W1966725788
- Cited by
- 110
- References
- 2
- FWCI
- 16.40
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.